Komori
Stella Pharma (4888) · InitiativeFirst stated

Development of a novel PET diagnostic agent targeting LAT1

First written in FY2026. . Latest entry: FY2026.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Joint research and development of the LAT1-targeted PET diagnostic agent 5-[18F]F-αMe-3BPAA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026First statedAnnual report

    「Through joint research with the Institute for Integrated Radiation and Nuclear Science, Kyoto University, and the Institute of Photobiomedical Science, Kansai Medical University, we developed a new PET diagnostic agent, 5-[18F]F-αMe-3BPA, targeting the amino acid transporter LAT1, which is highly expressed in cancer cells, and demonstrated its efficacy in animal models.」

    A new PET diagnostic agent, 5-[18F]F-αMe-3BPA, targeting LAT1 was developed through joint research, and its efficacy was demonstrated in animal models.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Stella Pharma yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Development of a novel PET diagnostic agent targeting LAT1 | STELLA PHARMA CORPORATION (4888) | Komori